39K

Centogene N.V. (39K)

Market Open
XMUN XMUN
5.35M Market Cap
- P/E Ratio
0% Div Yield
- Volume
- Eps
Previous Close
Day Range
0 0
Year Range
0 0
Want to track 39K and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

39K is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XMUN (EUR).

39K Chart

Similar

TOX
Touax
-
-
EV RESOURCES LTD.
-
-
92T
Mustang Energy Corp.
-
-
Hpi Ag
0.02
-71.01%
9LK
Lightning eMotors Inc.
0.44
0%

Centogene N.V. (39K) FAQ

What is the stock price today?

The current price is €0.00.

On which exchange is it traded?

Centogene N.V. is listed on XMUN.

What is its stock symbol?

The ticker symbol is 39K.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 5.35M.

Has Centogene N.V. ever had a stock split?

No, there has never been a stock split.

Centogene N.V. Profile

Professional Services Industry
Industrials Sector
Ms. Kim Stratton CEO
XMUN Exchange
- ISIN
Germany Country
384 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Centogene N.V. stands out in the global healthcare and biotechnology landscape as a leading biopharmaceutical research and diagnostics company with a focus on rare genetic diseases. Its core mission is to enhance the development and accessibility of novel treatments for these conditions through comprehensive genetic testing and diagnostics. By integrating clinical data with genetic and multi-omics insights, Centogene is at the forefront of addressing unmet medical needs across a variety of genetic disorders. This has not only positioned the company as an essential player in personalized medicine and precision diagnostics but also as a valuable partner for pharmaceutical and biopharmaceutical companies seeking to develop targeted therapies. Centogene's extensive database, enriched with epidemiological, clinical, and genetic information, facilitates groundbreaking research and the development of new treatments, thereby influencing the healthcare sector significantly. The company's contributions extend to hospitals, research institutions, and healthcare providers worldwide, solidifying its impact on the advancement of medical knowledge and treatments for rare genetic conditions.

Products and Services

  • Genetic Testing and Diagnostics

    Centogene's cornerstone is its advanced genetic testing and diagnostics services, designed specifically for the identification and understanding of rare genetic disorders. Utilizing cutting-edge technology, these services enable precise diagnosis, which is critical for the effective management and treatment of rare diseases. For patients and healthcare providers, this means access to crucial information that informs treatment decisions and care strategies.

  • Data-Driven Research

    The company leverages its vast repository of genetic, clinical, and epidemiological data to conduct in-depth research on rare diseases. This research is pivotal for the discovery of biomarkers, understanding disease mechanisms, and the development of new therapeutic approaches. Pharmaceutical and biopharmaceutical companies greatly benefit from these insights for the development of targeted therapies, making Centogene a key partner in drug development processes focused on precision medicine.

  • Comprehensive Database

    Centogene's comprehensive database is among its most valuable assets, containing a wealth of information, including epidemiological, clinical, and genetic data on rare diseases. This database serves as a crucial resource for researchers, healthcare professionals, and drug developers, facilitating the identification of trends, the discovery of novel treatments, and the advancement of knowledge in the field of rare genetic disorders. By contributing to the global understanding and management of these conditions, the database aids in the promotion of personalized medicine and improves patient outcomes.

Contact Information

Address: Am Strande 7
Phone: 49 381 80113 500